It goes without saying: 2020 was not the year we expected. What started with our most successful JP Morgan Conference ever quickly spiraled into something else entirely – a year marked by pervasive uncertainty, which wreaked havoc across the globe and fundamentally altered the way we think about human interaction, the immense privilege of good health and the critical importance of science.
Schedule a virtual 1x1 meeting with 75+ of our top-tier companies during the week of the Virtual J.P. Morgan Healthcare Conference, to be held on January 11 – 14, 2021.
Despite the holiday “break,” it’s been a very busy few weeks for Stern IR clients and we wanted to congratulate several on recent clinical, regulatory and corporate successes:
We hope you are all looking forward to some well-earned R&R over the Thanksgiving holiday – it’s been a wild few weeks for biotech!
Stern Investor Relations parent company, Precision Medicine Group, announced that it has completed a major investment and recapitalization led by funds managed by Blackstone, with significant participation from Precision’s co-founders, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT and Vida Ventures.
Let us begin by congratulating Stern IR client Gilead, who ranked highly in this year’s II awards across several metrics, including best investor relations program, best CEO and CFO, and best communication of strategy and risk management amid COVID-19. Go GILD!
We want to start by congratulating several Stern IR clients on major accomplishments, all from this week alone! We also have a 13F update, even more SPACs, and a market update.
#JPMorgan2021 – It’s Here!
Congratulating Stern IR clients, Atea Pharmaceuticals and Goldfinch Bio, who were named among Fierce Biotech’s 2020 Fierce 15, and Tmunity Therapeutics, who was named to the Endpoints 11!
Back to school and back to business, NASDAQ responds to the SEC’s proposed amendments to the 13F reporting threshold, and a market update.
